Walgreens Set to Go Private in Historic Deal with Sycamore Partners

In a significant move, Walgreens, the struggling drugstore giant, is poised to transition from a publicly traded company to a private entity after finalizing a deal with private equity firm Sycamore Partners. This marks the end of Walgreens’ nearly century-long history as a public company. The agreement, which was revealed Thursday, sets the value of Walgreens at approximately $10 billion in equity. When including debt and future payouts, the total transaction could reach as much as $23.7 billion.

Sycamore Partners will purchase Walgreens shares for $11.45 in cash, an 8% premium over the company’s Thursday closing price. Additionally, shareholders may receive up to $3 per share from the eventual sale of Walgreens’ primary-care businesses, which include Village Medical, Summit Health, and CityMD. The deal is expected to be finalized by the fourth quarter of this year.

A Tumultuous Public Journey

The decision to go private comes after a challenging period for Walgreens. While the company’s stock surged by 15% in early 2025, it had plummeted by over 48% compared to the previous year and had seen a staggering 70% decrease over the past three years. Walgreens, once a retail titan with a market valuation exceeding $100 billion in 2015, had seen its worth dip below $8 billion by late 2024. The company faced fierce competition from industry giants such as CVS, grocery chains, big-box retailers, and even the rise of online shopping giants like Amazon.

CEO Tim Wentworth, who took the reins at Walgreens in 2023, stated, “While we are making progress against our ambitious turnaround strategy, meaningful value creation will take time, focus, and change that is better managed as a private company.” He emphasized his confidence in Sycamore’s proven track record, particularly its success in managing retail turnarounds.

Sycamore’s Managing Director, Stefan Kaluzny, echoed Wentworth’s sentiments, highlighting Walgreens’ “pharmacy-led model” as a key asset for future success, one that can drive better outcomes for patients, customers, and communities.

Shifting Strategies and Store Closures

In line with its evolving strategy, Walgreens has been reducing its retail presence to cut costs, with plans to close 1,200 stores by 2027, including 500 closures in fiscal 2025 alone. The company cited factors such as market shifts post-pandemic, declining pharmacy reimbursements, and softer consumer spending as challenges that weighed on its performance.

While its competitor CVS expanded into insurance and pharmacy benefits, Walgreens chose to focus on its retail pharmacy services. This strategy, however, faltered as healthcare costs rose and patient preferences shifted. Walgreens also scaled back its stake in VillageMD, signaling a retreat from its primary-care ambitions.

Despite these hurdles, Walgreens remains a significant player, with over 310,000 employees and 12,500 retail pharmacy locations spanning the U.S., Europe, and Latin America. The company will continue to operate from its Chicago headquarters and is still set to release its second-quarter earnings report on April 8.

A New Chapter in Retail Healthcare

Walgreens’ decision to go private is not without precedent. In 2019, KKR considered a $70 billion buyout, but no deal materialized. Now, with Sycamore at the helm, Walgreens is presented with an opportunity to stabilize and reshape its business outside the watchful eyes of public market shareholders.

This deal is part of a broader trend within the retail healthcare industry, where companies are reevaluating their business models in the face of rapid changes. For Walgreens, the move to go private offers the flexibility to recalibrate and chart a more sustainable future.

As the company undergoes this historic transformation, the coming months will reveal whether Sycamore’s investment will ultimately pay off, shaping the future of one of America’s most iconic pharmacy chains.

For feedback: contact the BATV Editorial Division at: info@batvja.com